Sijie Huang

Sijie Huang

Auto-generated profile, based on publicly available information

Sijie Huang

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2022 in Science
Verified
Journal Article
Open access
WYWanchao Yin
Wanchao Yin
YXYouwei Xu
Youwei Xu
PXPeiyu Xu
Peiyu Xu
XCXiaodan Cao
Xiaodan Cao
CWCanrong Wu
Canrong Wu
HXH. Eric Xu
H. Eric Xu
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has become the dominant infective strain. We report the structures of the Omicron spike trimer on its own and in complex with angiotensin-converting enzyme 2 (ACE2) or an anti-Omicron antibody. Most Omicron mutations are located on the surface of the spike protein and change binding epitopes to many current antibodies. In the ACE2-binding site, compensating mutations strengthen receptor binding domain (RBD) binding to ACE2. Both the RBD and the apo form of the Omicron spike trimer are thermodynamically unstable. An unusual RBD-RBD interaction in the ACE2-spike complex supports the open conformation and further reinforces ACE2 binding to the spike trimer. A broad-spectrum therapeutic antibody, JMB2002, which has completed a phase 1 clinical trial, maintains neutralizing activity against Omicron. JMB2002 binds to RBD differently from other characterized antibodies and inhibits ACE2 binding.

24 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
PXPeiyu Xu
Peiyu Xu
SHSijie Huang
Sijie Huang
HZHuibing Zhang
Huibing Zhang
CMChunyou Mao
Chunyou Mao
XZX. Edward Zhou
X. Edward Zhou
HXH. Eric Xu
H. Eric Xu

15 August 2022 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
PXPeiyu Xu
Peiyu Xu
SHSijie Huang
Sijie Huang
SGShimeng Guo
Shimeng Guo
YYYing Yun
Ying Yun
XCXi Cheng
Xi Cheng
HXH. Eric Xu
H. Eric Xu

19 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
CYChongzhao You
Chongzhao You
YZYumu Zhang
Yumu Zhang
PXPeiyu Xu
Peiyu Xu
SHSijie Huang
Sijie Huang
WYWanchao Yin
Wanchao Yin
YJYi Jiang
Yi Jiang
Neuromedin U receptors (NMURs), including NMUR1 and NMUR2, are a group of Gq/11-coupled G protein-coupled receptors (GPCRs). NMUR1 and NMUR2 play distinct, pleiotropic physiological functions in peripheral tissues and in the central nervous system (CNS), respectively, according to their distinct tissue distributions. These receptors are stimulated by two endogenous neuropeptides, neuromedin U and S (NMU and NMS) with similar binding affinities. NMURs have gathered attention as potential drug targets for obesity and inflammatory disorders. Specifically, selective agonists for NMUR2 in peripheral tissue show promising long-term anti-obesity effects with fewer CNS-related side effects. However, the mechanisms of peptide binding specificity and receptor activation remain elusive. Here, we report four cryo-electron microscopy structures of Gq chimera-coupled NMUR1 and NMUR2 in complexes with NMU and NMS. These structures reveal the conserved overall peptide-binding mode and the mechanism of peptide selectivity for specific NMURs, as well as the common activation mechanism of the NMUR subfamily. Together, these findings provide insights into the molecular basis of the peptide recognition and offer an opportunity for the design of the selective drugs targeting NMURs.

8 July 2021 in Cell Research
Verified
Journal Article
Closed access
PDF file
SHSijie Huang
Sijie Huang
PXPeiyu Xu
Peiyu Xu
YTYangxia Tan
Yangxia Tan
CYChongzhao You
Chongzhao You
YZYumu Zhang
Yumu Zhang
HXH. Eric Xu
H. Eric Xu

25 April 2025 in Science Advances
Verified
Journal Article
Open access
TDTyler Detomasi
Tyler Detomasi
Gilles DegotteGilles Degotte
Gilles Degotte
SHSijie Huang
Sijie Huang
RSRahul K. Suryawanshi
Rahul K. Suryawanshi
ADAmy Diallo
Amy Diallo
CCCharles Craik
Charles Craik
The main protease (M Pro ) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a validated drug target. Starting with a lead-like dihydrouracil chemotype identified in a large-library docking campaign, we improved M Pro inhibition >1000-fold by engaging additional M Pro subsites and using a latent electrophile to engage Cys 145 . Advanced leads from this series show pan-coronavirus antiviral activity, low clearance in mice, and for AVI-4773 , a rapid reduction in viral titers >1,000,000 after just three doses. Both compounds are well distributed in mouse tissues, including brain, where concentrations >1000× the 90% effective concentration are observed 8 hours after oral dosing for AVI-4773 . AVI-4516 shows minimal inhibition of major cytochrome P450s and human proteases. AVI-4516 also exhibits synergy with the RNA-dependent RNA polymerase inhibitor, molnupiravir, in cellular infection models. Related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus. The properties of this chemotype are differentiated from existing clinical and preclinical M Pro inhibitors and will advance therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses.